eli lilly oral tirzepatide Lilly's investigational GLP-1, orforglipron, delivered superior blood glucose reduction and weight loss across three pivotal phase 3 diabetes trials, including outperforming oral semaglutide in the head-to-head study. The results further Orforglipron: Eli Lilly's New Oral

Neither is currently covered by the HSE or the Drugs Payment Scheme for weight management, though reimbursement assessments are ongoing via NCPE

Precision-Formulated, GMP-Certified Products Our GMP-certified manufacturing ensures that every weight management solution we produce meets the highest standards of quality, safety, and efficacy

do not use if you have a history of severe gastrointestinal disease Signs of low blood sugar (for example, dizziness, weakness, shakiness, jitteriness, headache, anxiety/mood changes, rapid heartbeat, confusion, slurred speech, sweating, or lightheadedness) While this is rare with GLP-1s, if it occurs, please seek in-person care immediately

Tricyclic antidepressants like amitriptyline can also cause weight gain

Semaglutide Versus Liraglutide and Placebo for Weight Loss in Patients with Type 2 Diabetes (SUSTAIN 7): A Randomized, Double-Blind, Phase 3 Trial